FIELD: biotechnology.
SUBSTANCE: invention relates to activated antibodies, and can be used in medicine for the treatment of oncological diseases. Recombinantly, a modified antibody is obtained containing a masking portion, a cleavable portion, and two linkers. The resulting antibody is used to prepare a pharmaceutical composition that can be used to treat a solid tumor associated with excessive expression or activity of VEGF and inhibition of angiogenesis.
EFFECT: invention makes it possible to obtain an antibody capable of specifically binding to a target antigen after activation of the antibody by cleavage with legumain.
31 cl, 36 dwg, 59 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED ANTIBODIES COMPOSITION, METHODS OF PRODUCTION AND APPLICATION | 2010 |
|
RU2636046C2 |
| SUBSTRATES OF MATRIX METALLOPROTEINASE AND OTHER CLEAVABLE MOIETIES AND METHODS FOR USE THEREOF | 2014 |
|
RU2715232C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF | 2014 |
|
RU2815683C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION | 2014 |
|
RU2727836C2 |
| ACTIVATED ANTIBODIES WHICH BIND TO EPIDERMAL GROWTH FACTOR RECEPTOR, AND METHODS FOR USE THEREOF | 2013 |
|
RU2713121C2 |
| ANTI-CD71 CONJUGATES ACTIVATED ANTIBODY-DRUG AND THEIR APPLICATION METHODS | 2018 |
|
RU2771292C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| NUCLEIC ACID STRUCTURE FOR EXPRESSION OF ACTIVE SUBSTANCES THAT CAN BE ACTIVATED BY PROTEASES, PREPARING AND USING | 1998 |
|
RU2204414C2 |
| CONDITIONALLY ACTIVE BIOLOGICAL PROTEINS | 2016 |
|
RU2733658C2 |
